Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2019-004476-19Phase 2Completed
Phase 2, randomised trial of autologous bone-marrow mesenchymal stem cells in degenerative disc disease (DDD) (2 arms), sponsored by Università Campus Bio-Medico di Roma. Primary endpoint: Responder efficacy at 12 months. Started Jan 2021; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on 2019-004476-19.